Business Context and Reporting Period
This Form 8-K, dated April 26, 2026, reports that Organon & Co. (NYSE: OGN) has entered into a definitive Agreement and Plan of Merger with Sun Pharmaceutical Holdings USA, Inc. ("Parent"). Under the agreement, a wholly-owned subsidiary of Parent will merge with Organon, with Organon surviving as a wholly-owned subsidiary of Parent. The filing also announces the permanent appointment of Joseph Morrissey as Chief Executive Officer and Carrie S. Cox as Executive Chair.
Key Financial Metrics and Transaction Terms
- Merger Consideration: $14.00 per share in cash.
- Premium: Represents a 103% premium to the closing share price on April 9, 2026.
- Financing: Parent has secured committed debt financing sufficient to fund the transaction and refinance or repay certain existing Organon debt.
- Termination Fee: Organon is required to pay a $120,000,000 termination fee to Parent under specific circumstances, such as accepting a superior proposal.
- Equity Treatment:
- Options: In-the-money options will be cashed out; out-of-the-money options will be cancelled for no consideration.
- RSUs (Pre-2026): Will accelerate and be converted to cash.
- RSUs (2026+): Will be converted to cash-based successor awards subject to original vesting terms.
- PSUs (Pre-2026): Will accelerate and be converted to cash based on target performance.
- PSUs (2026+): Will be converted to cash-based awards; performance conditions will be removed, and awards will vest based on service.
Note: This filing does not provide Organon's current revenue, profit, cash flow, or debt levels. It only references the refinancing of "certain existing debt."
Material Changes and Conditions
The transaction is subject to several material conditions, including:
- Approval by holders of a majority of outstanding shares (Requisite Company Vote).
- Expiration of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act and receipt of non-U.S. antitrust and foreign direct investment approvals.
- Absence of any law or order prohibiting the merger.
- Absence of a Material Adverse Effect on the Company.
- Receipt of regulatory approvals without terms constituting a "Substantial Detriment."
Upon consummation, Organon's shares will be delisted from the NYSE and deregistered under the Exchange Act within ten days.
Guidance, Outlook, and Risks
Outlook and Timeline: The Merger Agreement includes a "drop-dead" date of January 26, 2027, which may be extended if only regulatory conditions remain outstanding. Management is committed to using reasonable best efforts to obtain approvals.
Risks and Contingencies:
- Regulatory Risk: Failure to obtain necessary antitrust or foreign investment approvals could prevent closing.
- Termination Risk: The agreement may be terminated if a superior proposal is accepted (triggering the $120 million fee), if the Company Board changes its recommendation, or if the transaction is not completed by the deadline.
- Operational Risk: Potential disruption to business operations, retention of key personnel, and relationships with customers and suppliers during the pendency of the merger.
- Legal Risk: Potential stockholder litigation and associated defense costs.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement filed as Exhibit 2.1.
- Monitor the status of regulatory approvals, particularly under the Hart-Scott-Rodino Act and foreign jurisdictions.
- Review the upcoming Merger Proxy Statement (Schedule 14A) for detailed financial data and voting procedures.
- Confirm the specific vesting and payout calculations for individual equity awards (Options, RSUs, PSUs) based on grant dates.
- Assess the likelihood of the transaction closing before the January 26, 2027 deadline.